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Sustained release of usnic acid 
from graphene coatings ensures 
long term antibiofilm protection
Santosh Pandit1, Shadi Rahimi1, Abderahmane Derouiche1, Athmane Boulaoued2 & 
Ivan Mijakovic1,3*
Protecting surfaces from bacterial colonization and biofilm development is an important challenge 
for the medical sector, particularly when it comes to biomedical devices and implants that spend 
longer periods in contact with the human body. A particularly difficult challenge is ensuring long-term 
protection, which is usually attempted by ensuring sustained release of antibacterial compounds 
loaded onto various coatings. Graphene have a considerable potential to reversibly interact water 
insoluble molecules, which makes them promising cargo systems for sustained release of such 
compounds. In this study, we developed graphene coatings that act as carriers capable of sustained 
release of usnic acid (UA), and hence enable long-term protection of surfaces against colonization 
by bacterial pathogens Staphylococcus aureus and Staphylococcus epidermidis. Our coatings 
exhibited several features that made them particularly effective for antibiofilm protection: (i) UA was 
successfully integrated with the graphene material, (ii) a steady release of UA was documented, (iii) 
steady UA release ensured strong inhibition of bacterial biofilm formation. Interestingly, even after 
the initial burst release of UA, the second phase of steady release was sufficient to block bacterial 
colonization. Based on these results, we propose that graphene coatings loaded with UA can serve as 
effective antibiofilm protection of biomedical surfaces.
Bacterial growth, surface colonization and subsequent biofilm formation is one of the major challenges for bio-
medical  devices1,2. The biofilm formation is considered as a key factor for majority (˃ 60%) of bacterial infections 
such as cystic fibrosis, nonhealing wounds and medical device associated infections in humans  worldwide3,5. The 
bacterial community inside biofilms represents a protected mode of survival, due to the presence of exopolymeric 
substances which allows bacteria to thrive in hostile  environments6–9. Bacterial cells in biofilms are found to be 
100–1000 times more resistant to antibiotics than bacterial cells in planktonic state, leading to higher risks of 
treatment failure by developing antibacterial  resistance10–12. Most biomedical devices in contact with the human 
body are always at risk of bacterial colonization, and this leads to device-associated infections, which often lead to 
failure of such devices, patient suffering and financial  losses13,14. Hence, there is significant incentive to develop-
ment of antibacterial coatings to prevent or minimize bacterial attachment to biomedical surfaces.
Many nanomaterials are known to exhibit strong antibacterial  effects15,16. For example, antibacterial activity 
of graphene and its derivatives has been documented  extensively17–21. Similarly, direct antibacterial effects of 
metalling nanoparticles have been frequently reported. Antimicrobial activity of silver nanoparticle is widely 
studied and demonstrated to have strong bactericidal  effect22,23. However, the ability of these nanomaterials 
and nanoparticles to protect surfaces over extended periods of time is questionable. In past decade, combining 
nanomaterials with antibiotics to enhance the antibacterial efficiency was intensively explored 24–26. Metallic 
nanoparticles are not particularly suitable for long-term protection, as they are not chemically inert and release 
metal ions that may be toxic to mammalian  cells27,28. By contrast, graphene and its derivatives are chemically inert 
and possess excellent physicochemical properties for long-time protection, such as high thermal stability, bio-
compatibility, and high mechanical strength. Therefore, they could provide the optimal cargo system for sustained 
drug release to ensure long-term antibacterial protection of biomedical  devices29,30. There are a few available 
studies showing the loading of antibiotics and other therapeutics to graphene derivatives, which have resulted in 
sustained drug release and enhancement in antimicrobial  activity31,32. However, these tests were performed only 
against planktonic state of bacterial cells, which are highly sensitive to antibiotics in compared to sessile cells.
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It should be mentioned that graphene coatings themselves may be engineered to provide a degree of antibac-
terial activity, which is based on direct mechanical interaction of bacterial cells with the exposed sharp edges of 
 graphene17,18. To maximize this effect, graphene coatings/flakes need to be oriented perpendicular to the surface. 
Graphene coatings where flakes are predominantly arranged parallel to the surface and have no exposed edges 
available for interaction with bacterial cells, are typically not  bactericidal17,18,20. Such planar or parallel-to-the-
surface coatings have a high adsorption capacity, which in fact directly favours the adhesion of bacterial cells 
and promotes biofilm  growth33,34.
UA is a secondary metabolites of sea lichen with strong antibacterial  activity35. Sea lichens are surface-attached 
symbiotic communities composed of fungi and algae or bacteria. By producing antibacterial compounds such as 
UA, lichens protect themselves from colonization of surrounding bacterial communities. Considering the inhibi-
tory activity of UA on bacterial colonization, the potential of UA to prevent surfaces of biomedical devices has 
already been  proposed36. Strong antibacterial activity of UA against various human pathogens was demonstrated 
by previous  studies35,36. This activity of UA is mainly based on its inhibitory potential on nucleic acid synthesis, 
which, via inhibiting RNA synthesis also blocks bacterial  translation35. UA has been used as an antibacterial addi-
tive in medicinal products, toothpaste, mouth wash, wound healing patches and creams. However, poor solubility 
of UA limits its medical  application37. In order to improve delivery and expand the scope of antibacterial applica-
tions of UA, this bioactive molecule has been incorporated into liposomes, nano emulsions and polymeric and 
metallic  nanoparticles37,38. These strategies were effective in delivery of UA for several applications, e.g. wound 
treatment and targeted delivery into macrophages infected with Mycobacterium tuberculosis37,38.
In this study, we attempted to develop graphene coatings loaded with UA, which would be capable of sus-
tained UA release and thereby providing long-term antibiofilm protection. the effectiveness of our coatings was 
evaluated against planktonic state and early- and late-stage biofilms of opportunistic pathogens S. aureus and S. 
epidermidis. These pathogens often colonise to biomedical implants, forms biofilms, infect surrounding tissues 
and leads towards the implant failure. We found that our coatings provide a sustained release of UA for up to 
one week, and we found them to be extremely effective against all forms bacterial that we tested, for periods 
of up to 96 h. Even after the primary burst release of UA during the initial 24 h, the coatings retained excellent 
antibiofilm properties. Our results indicate that this combination of graphene coatings and UA could pave the 
way for more effective antibacterial protection of biomedical devices, leading to diminished risks of device-
associated infections.
Materials and methods
Bacterial strains, chemicals and materials. The graphene flakes (powder form) was purchased from 
Graphitene (UK). The usnic acid (UA) was purchased from Sigma-Aldrich and dissolved in DMSO. The S. 
epidermidis ATCC 35,984 and S. aureus CCUG10778 were used to evaluate the antibacterial and antibiofilm 
activity. Tryptic soy broth (TSB)/agar was used to grow bacteria.
UA attachment to graphene. The graphene flakes were dispersed in deionized and double distilled water 
by ultrasonication (125 W) for 4 h at the concentration of 2 mg/mL as a stock solution. Parallelly, UA was dis-
solved in di-methyl sulfoxide (DMSO; 100%) at the concentration of 5 mg/mL. By mixing these stock solutions 
to sterile water, various concentrations of graphene—UA mixture were prepared: total concentrations of 200 µg/
mL, 100 µg/mL, 50 µg/mL and 25 µg/mL. All mixtures contained equal concentrations of graphene and UA 
(1:1 molar ratio) in sterile water with 5% of DMSO. For example, 200 µg/mL of mixture containing final con-
centration of 200 µg/mL of graphene and 200 µg/mL of UA in sterile water with 5% of DMSO. After mixing, all 
mixtures were further sonicated for 4 h. After the sonication, graphene flakes loaded with UA were separated 
by centrifugation at 10,000 rpm for 15 min. The flakes were further washed twice with deionized and double 
distilled water. The washed flakes were mixed in original volume of sterile deionized water and further sonicated 
for 2 h to achieve homogeneous dispersion.
Surface coatings and characterization. Round cover glasses (15 mm diameter) were washed with iso-
propyl alcohol, followed by 70% ethanol and dried by air drier. Clean and dried glass surfaces were coated 
with various concentrations of graphene flakes loaded with UA (25, 50, 100 and 200 µg/mL) and non-loaded 
graphene flakes (100 µg/mL) as control, by using a drop casting method. Specifically, 400 µL of each batch of dis-
persed graphene flake solution was placed on a glass surface and left overnight for complete drying at 37 °C. The 
dried surfaces were further cured at 60 °C for 12 h. The coated surfaces were subsequently washed with sterile 
deionized water to remove the flakes that were not attached to the glass surface dried at 60 °C.
The morphology of coatings was examined by scanning electron microscopy (JEOL JSM 6301F). The gra-
phene coatings were further coated with gold (5 nm) prior to SEM imaging. Infrared spectra of the samples were 
recorded using an attenuated total reflection (ATR) Alpha FT-IR spectrometer from Bruker, with a diamond 
crystal as refractive element, in the range of 400–3000  cm−1 and at a resolution of 2  cm−1. Raman spectra were 
measured by a Dilor LabRAM confocal micro‐Raman spectrometer equipped with a 50 × objective and a HeNe 
laser (632.8 nm). Each spectrum was recorded in the range 500–3000  cm-1 with 10 min accumulation time and 
approximately 4  cm−1 resolution.
Evaluation of UA release. To examine the UA release pattern from the loaded graphene flakes in the 
coatings, a coated cover glass was transferred to a 15 ml of falcon tube containing 1 ml of PBS buffer (pH 7.4) 
and kept at 37 °C. After 24 h, the buffer with released UA was collected from the tube and replaced with fresh 
buffer. The procedure was repeated every 24 h, for a total of 7 days. All collected samples were freeze dried and 
resuspended in 100 µl of milli-Q water. The amount of released UA was quantified by using HPLC (Dionex 
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UHPLC-PDA-FLD) with the column AAA C-18 5 mm (150 mm × 4.6 mm) (AB Sciex Pte. Ltd., USA). A mixture 
of methanol—water—acetic acid (80:15:5 v/v) was used as the mobile phase with a flow rate of 1 mL/min. 10 µl 
of all the resuspended released samples and standard solutions of UA (from 1.56 to 100 µg/ml) were injected to 
HPLC quantified by comparison of peaks to a standard curve.
Time kill assay. The bactericidal efficiency of UA loaded on graphene was tested against the planktonic cells 
of S. aureus and S. epidermidis. To prepare bacterial inoculum, single colony of S. aureus and S. epidermidis was 
inoculated to 5 mL of growth medium (TSB) and incubated overnight at 37 °C with continuous agitation. For 
this assay, 20 µl of inoculum (2–5 ×  107 CFU/mL bacterial cells) from overnight grown bacterial cultures were 
inoculated into fresh TSB medium containing sterile deionized water (control), 12.5, 25, 50, 100 and 200 µg/mL 
of UA loaded graphene. All samples were incubated at 37 °C with continuous agitation for 24 h. A fraction of 
culture (100 µL) from each sample was taken for determination of bacterial viability at time points of 0, 2, 4, 6, 
8 and 24 h. The collected samples were serially diluted in 0.89% of saline. From the diluted samples, 100 µL was 
plated onto TSB agar plates, incubated at 37 °C for 48 h and the number of colonies was counted.
Antibiofilm assays. The biofilm inhibitory efficiency of coatings was evaluated against S. aureus and S. 
epidermidis. The graphene samples loaded with UA and control glass surfaces were sterilized by UV-light expo-
sure for 10 min. The overnight culture of respective bacteria was diluted in fresh TSB broth to obtain the final 
inoculum of 2–5 ×  106 CFU/mL and 400 µL inoculum was seeded on the pre-sterilized coated and non-coated 
surfaces. Samples with bacterial inoculum were incubated at 37 °C for 24 h without agitation to allow for for-
mation of biofilms. After 24 h of growth, samples were washed twice with sterile deionized water to remove the 
loosely adhered or free bacterial cells and collected in 5 mL of 0.89% of sodium chloride solution. The biofilms 
were detached from the surface and homogenized by sonication (30 s; 10% of amplitude). The homogenized 
biofilm suspensions were serially diluted into 0.89% of sodium chloride solution and plated onto TSB agar plates. 
Agar plates were incubated at 37 °C for 48 h and the number of colonies was counted. The density of biofilms 
and morphology of bacterial cells in biofilms were examined by using SEM. For this, biofilms of S. aureus and S. 
epidermidis formed on coated and non-coated surfaces were washed twice and fixed with 3% of glutaraldehyde 
for 2 h. The fixed biofilms were dehydrated by using graded series of ethanol concentrations (40%, 50%, 60%, 
70%, 80%, and 90%) for 15 min each, and with absolute ethanol for 20 min. The dehydrated biofilms were dried 
overnight at room temperature and sputter coated with gold (5 nm) prior to SEM imaging. The SEM images were 
acquired by using JEOL JSM 6301F (Carl Zeiss AG, Jena, Germany). To visualize the density of live and dead 
bacterial cells in biofilms grown on the coated and noncoated surfaces, biofilms were stained with the mixture of 
6.0 μM SYTO 9 and 30 μM potassium iodide from Live/Dead BacLight Viability kit L13152, (Invitrogen, Molec-
ular Probes, Inc. Eugene, OR, USA). Fluorescence microscopic images of the stained biofilms were acquired by 
using a Zeiss fluorescence microscope (Axio Imager.Z2m Carl Zeiss, Jena, Germany).
To evaluate the long-term anti-biofilm potential of coatings, biofilms were grown on the coated and non-
coated surfaces for 96 h. Briefly, overnight grown bacterial suspension was inoculated on the surfaces and incu-
bated at 37 °C for 96 h. The culture medium was replaced in the interval of 24 h (once a day, 3 times in total). 
After 96 h, the biofilms were collected and homogenized by means of sonication and plated on agar plates after the 
serial dilution to count the colonies. In addition, antibiofilm activity of coatings after the primary phase of drug 
release was also evaluated. In order to test this, the sterile TSB medium was placed onto the pre-sterilize coated 
and noncoated surfaces and incubated at 37 °C for 24 h, to allow for initial release of UA. After this incubation, 
the medium was removed, and surfaces were washed twice with sterile deionized water to remove any traces of 
the medium with released UA from the coatings. Thereafter, fresh TSB medium containing 2–5 ×  106 CFU/mL 
of respective bacterial inoculum was added onto the surfaces and incubated at 37 °C for 24 h. The number of 
viable bacterial cells in biofilms and visualization of live and dead bacterial cells were determined by using the 
methods described above.
Statistical analysis. All data are presented as the mean ± standard deviation from at least three different 
biological replicates. Intergroup differences were estimated by one-way analysis of variance (ANOVA), followed 
by a post hoc multiple comparison (Tukey) test to compare the multiple means. Differences between values were 
considered statistically significant when the P-value was < 0.05.
Results and discussion
Large quantities of crystalline UA can be successfully loaded onto graphene coatings. UA was 
loaded onto graphene by a simple process of mixing in solution, facilitated by ultrasonication. The glass surfaces 
were coated with different concentrations of UA-loaded graphene. FT-IR, Raman spectroscopy and high-reso-
lution scanning electron microscope (SEM) analysis were used to characterize the structure and morphology of 
the coatings and to assess the success of UA loading, as presented in Fig. 1. The usual Raman peaks of graphene 
were detected. The D peak (~ 1326  cm−1) related to defects (edges) and G peak (~ 1585  cm−1) from the  sp2 C–C 
bond denoted the degree of graphitization of  material39. The intensity of the D band was observed to be higher 
compared to the G band, indicating a considerable amount of defects and roughness of the coating surfaces. For 
both graphene and UA integrated samples, the minor 2D peak was identified, demonstrating the abundance of 
multilayer graphene in the surface (Fig. 1a)40.
The calculated ratio between the intensities of the D and the G bands  (ID/IG) was observed to be slightly 
higher in the graphene loaded with UA than in pure graphene (Gr is 1.26, Gr + UA is 1.34). This ratio is known 
to be inversely proportional to the crystallite size of nanographite. This suggests the presence of shorter graphene 
sheets due to some changes in the amount of defects and hinting to sites where UA attaches.
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In our FT-IR spectroscopy analysis (Fig. 1b), most peaks related to UA were clearly observed in the samples 
of graphene loaded with UA, with no significant peak shift. This suggests a preservation and effective integration 
of UA molecules with the graphene matrix. Next, the coatings of graphene and graphene loaded with UA were 
examined by SEM. The quantity of graphene in coatings with lower concentration of graphene loaded with UA 
(25 µg/mL) were insufficient to cover the surface, showing islands of graphene particles and patches of uncoated 
surface. With concentrations of graphene loaded with UA ≥ 50 µg/mL, the coatings were distributed homoge-
neously and covered the entire surface, with no significant clumping or aggregation of particles (Fig. 1c). The 
high-resolution SEM images of loaded and unloaded graphene coatings showed a homogenous distribution of 
crystalline form of UA on graphene surface (Fig. 1d), confirming successful loading.
Release of UA loaded on graphene coatings is stable over prolonged periods. Sustained release 
of antibacterial drugs over extended time periods is crucial for long-term antibiofilm protection of biomedical 
surfaces. Hence, we examined the release pattern of UA loaded onto graphene coatings for up to 7 days, using 
HPLC (Fig. 2). After the initial burst release, where close to 40 µg of UA were released during day 1, the release 
of UA remained stable at values ranging between 20 and 30 µg/day. The sustained release of UA from coatings is 
due to the multiple layers of graphene present on the coated surface, each of which can gradually release UA and 
due to the slow dissolving rate of crystalline form of UA integrated to graphene. It is previously demonstrated 
that integration of crystalline UA aggregates in nanomaterials slowly dissolved from coatings to medium or 
buffer, leading to a controlled and sustained release for longer  times41.
Graphene loaded with UA prevents planktonic growth of bacteria. Antibacterial effects of our 
graphene loaded with UA were tested against opportunistic pathogens S. aureus and S. epidermidis. Initially, 
we tested the bacterial toxicity of graphene flakes loaded with UA in solution, where both the bacterial cells 
and the graphene-UA flakes are freely floating. Both bacterial strains were grown in the nutrient rich medium 
with continuous agitation (at 37 °C shaking incubator; 300 rpm), in the presence of different concentrations of 
graphene-UA flakes. The viability of planktonic bacteria was followed for 24 h of growth (Fig. 3).
Previous reports of UA toxicity against S. aureus and methicillin resistant S. aureus indicated maximum 
killing effects up to 8 h of treatment, with no further increase in bactericidal activity between 8 and 24  h35. In 
Figure 1.  Raman spectra (a) and FT-IR spectra (b) of coatings made of graphene and graphene loaded with 
UA, with free UA as control. (c) Morphology of surface coatings with different concentrations of graphene 
loaded with UA. (d) High resolution SEM images of surfaces coated with graphene and graphene loaded with 
UA (100 µg/mL). The red arrow is pointing to UA in crystalline form, attached to graphene flakes.
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our experiments, UA loaded onto graphene flakes had more extended toxicity, with significant killing effect 
recorded also after 8 h (Fig. 3). The killing effect was directly proportional to the concentration of graphene-UA 
flakes. The lowest concentration (12.5 µg/mL) of graphene-UA flakes was bacteriostatic for the initial 2–8 h after 
treatment (Fig. 3a). All other concentrations were bactericidal against both S. aureus and S. epidermidis already 
from the first time point (2 h), and their bactericidal effects continued for the entire duration of the experiment 
(Fig. 3a,b). S. epidermidis was observed to be slightly more sensitive than S. aureus (Fig. 3b). Our conclusion was 
that graphene-UA flakes effectively prevent planktonic growth and are even capable of decimating planktonic 
bacteria (CFU reduction by  log10) within a 24-h period.
Graphene loaded with UA provides a coating that strongly mitigates biofilm formation. Adhe-
sion of bacterial cells and subsequent biofilm formation is one of the great challenges for biomedical  devices1,2,42. 
One promising strategy to reduce the adhesion of bacterial cells and prevent biofilm formation is to protect the 
surface of biomedical devices by various  coatings13,43. The coating strategies reported so far include coatings 
containing antibiotics, containing nanoparticles with antibacterial effects, containing carbon-based materials, 
containing antibacterial polymers and finally, coatings made of hybrid nanomaterials loaded with antibacterial 
 molecules43. So far, the major risk associated with coatings containing antibiotics/antibacterial agents is the rapid 
drug release, which precludes these coatings from delivering long-term antibacterial effects, and increases the 
risk of resistance development 44,45. To address this drawback, different strategies have been proposed, such as 
incorporation of antibiotics into a polymeric matrix, integration into nanomaterials, loading onto nanofibers 
followed by layer-by-layer deposition for sequential and sustained release of antibiotics/antibacterial44,45. Using 
these approaches, several classical antibiotics, such as gentamycin, vancomycin and rifampicin, have been used 
for implant coatings as a prophylactic measure against implant-associated  infections44,45. An ideal coating system 
should be able to ensure sustained release of the drug following a two-phase profile: a first stage of burst release, 
followed by sustained release capable of maintain a local drug concentration above the minimum inhibitory 
 concentration46,47.
Figure 2.  The release pattern of UA from the graphene coatings loaded with UA. The release pattern of UA was 
tested by using 200 µg/mL of UA loaded graphene coatings (15 mm of glass surface). The presented values are 
micrograms of UA detected in total volume of sample recovered from one coated surface. Data represent the 
mean ± standard deviation of two independent biological replicates.
Figure 3.  CFU counts of a) S. aureus and b) S. epidermidis exposed to different concentration of graphene-UA 
flakes (concentrations and colour coding are indicated in the figure inset) and grown in standard cultivating 
conditions. Data are presented as mean ± standard deviation from three independent biological replicates.
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Biofilm inhibitory efficiency of our coatings based on graphene loaded with UA was examined with the same 
two pathogens, S. aureus and S. epidermidis. Bacterial biofilms were grown on coated and non-coated control 
surfaces for 24 h. Thereafter, viability of bacteria in biofilms was evaluated by CFU counts and live/dead staining 
(Fig. 4). Coatings containing only graphene, not loaded with UA, exhibited no antibiofilm effects. Considering the 
fact that graphene flakes in the coating are mainly oriented parallel to the surface, with very few exposed edges 
(Fig. 1d) is not bactericidal, this result was in line with our expectations and with the available  literature17,48. The 
coatings based on graphene flakes loaded with UA (Fig. 1d) inhibited formation of S. aureus and S. epidermidis 
biofilms by a factor of > 1000 (3  log10 units) at all tested concentrations (25–200 µg/mL), except for S. aureus at 
25 µg/mL (Fig. 4a,b). Beyond 50 µg/mL, the inhibition in biofilm formation was not correlated to increasing 
concentration of graphene-UA flakes, indicating that a threshold concentration was achieved. A small difference 
in the sensitivity of S. aureus and S. epidermidis is probably due to the differences of bacterial surface, which is 
strain dependent. This difference is also reflected in the sensitivity of planktonic bacteria. (Fig. 3). The observed 
overall reduction in CFU counts (Fig. 4a,b) might be either due to the inhibitory activity on bacterial adhesion 
or due to the bactericidal activity of released drug from coatings. To distinguish between these two effects, we 
directly examined the biofilms on coated surfaces by fluorescence microscopy, after staining with live/dead 
viability stain (Fig. 4c). No dead cells were observed in the absence of UA, and no loss of bacterial adhesion was 
observed with control graphene coatings (not loaded with UA). The presence of UA in the coatings provoked 
appearance of dead cells (stained red), but the proportion of live/dead cells remained more or less constant with 
varying concentration of graphene-UA flakes. The obvious effect of increasing graphene-UA flake concentration 
was that of detecting fewer attached bacterial cells overall, indicating that these coatings, in addition to killing 
bacteria, effectively prevent early stages of bacterial colonization of the protected surface (Fig. 4c).
Figure 4.  Measurement of biofilm inhibitory efficiency of graphene (Gr) and UA loaded graphene coatings 
against (a) S. aureus and (b) S. epidermidis. Viability of bacteria, expressed as CFU counts, was determined 
after 24 h of growth on coated and non-coated surfaces. Data represent mean ± standard derivation from three 
independent biological replicates. *P < 0.05, **P < 0.0001. (c) Live/dead viability staining of biofilms of S. aureus 
and S. epidermidis performed on the same set of surfaces as above. Representative fluorescence microscopic 
images from three independent biological replicates are presented. Green color denotes live bacteria and red 
color denotes dead bacteria.
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Further, to examine the morphological alterations by UA released from our coatings, biofilms were examined 
by SEM. Compared to live/dead staining, a similar trend was with the SEM analysis. Non-coated and graphene 
coated surfaces harboured dense biofilm structures, with some exopolysaccharide matrix (Fig. 5). Very few bacte-
rial cells were detected on surfaces coated with graphene flakes loaded with UA. Surfaces coated with 25 µg/mL 
flakes harboured a slightly higher numbers of S. aureus microcolonies and aggregated cells (Fig. 5a), compared 
to S. epidermidis (Fig. 5b). The extent on morphological disruption of bacterial cells was more extensive in S. 
epidermis, corroborating our findings that this strain is more sensitive to UA. Overall, we conclude that three 
independent methods: CFU counts, live/dead staining and SEM analysis all conclusively point to a very strong 
inhibition of S. aureus and S. epidermidis biofilm formation on surfaces coated with graphene-UA flakes.
Biofilm inhibition by graphene-UA coatings persists after the primary release of UA. Since our 
graphene loaded with UA exhibited close to ideal behaviour in terms of sustained release (Fig. 2)46,47, we asked 
whether antibiofilm effects of our coatings would also persist for longer time periods. Long-term protection 
is vital for surfaces of biomedical devices, because the bacterial adhesion and biofilm formation in vivo takes 
longer time compared to in vitro experimental setups, where large numbers of bacterial cells are inoculated and 
there is no competition for surface attachment by host  cells49.
To evaluate the long-term antibiofilm activity, viability of biofilms on various coatings was examined after 
96 h, using CFU counts (Fig. 6a,b). Coatings with graphene flakes loaded with UA at concentrations ≥ 50 µg/ml 
Figure 5.  Representative scanning electron microscopic images of (a) S. aureus and (b) S. epidermidis biofilms 
grown on the non-coated (Control), graphene-coated (Gr) and surfaces coated with various concentrations of 
graphene loaded with UA. The biofilms were fixed, dehydrated and coated with gold before SEM imaging.
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dramatically reduced the viability of cells in biofilms of both bacterial species. Interestingly, the effect was much 
stronger than the one we measured after 24 h. Compared to a 1000-fold (3  log10 units) decrease at 24 h, after 96 h 
the decrease was closer to 100,000-fold (5  log10 units). This observation can be corelated to sustained release of 
UA (Fig. 2), which effectively prevents biofilm growth for extended time periods.
To further challenge our coatings, next we decided to test their antibiofilm effectiveness after completely 
removing the initial burst release of UA. To do this, surfaces coated with graphene flakes loaded with UA were 
primarily exposed to a sterile medium for 24 h. After 24 h, the medium containing primarily release UA was 
removed. The treated surfaces were then inoculated with a medium containing bacterial cells and incubated 
to allow for biofilm formation. Biofilm formation was followed by CFU counts and live/dead viability staining 
(Fig. 7a,b).
After the primary release, coatings with 25 and 50 µg/mL of graphene flakes loaded with UA were not able to 
inhibit bacterial growth to the extent that was observed when the primary release was present (Fig. 4). However, 
as shown in Fig. 7a,b, 100 and 200 µg/mL of coating showed full capacity for biofilm inhibition, reducing viable 
cell counts by > 1000-fold (> 3  log10 units), which was similar to inhibitory effects obtained during primary phase 
of UA release (Fig. 4). These results were fully confirmed by live/dead staining (Fig. 7c), where coatings with 
100 and 200 µg/mL of graphene flakes loaded with UA were almost devoid of bacterial cells and harboured only 
small microcolonies or individual cells. Overall, our data indicate that graphene flakes loaded with UA provide 
coatings with excellent antibiofilm properties. They ensure sustained delivery of UA for up to 7 days, offer full 
antibiofilm protection up to 96 h (Fig. 6a,b) and their antibiofilm activity does not depend exclusively on the 
initial burst release. Rather, at flake concentrations of 100 µg/mL and above, their residual release, after removal 
of the burst release, is fully capable of preventing bacterial attachment (Fig. 7). The observed antibiofilm activity 
is solely due to the sustained release of UA from graphene coatings. The UA is widely known as a strong inhibitor 
of nucleic acid synthesis in bacteria by disrupting the RNA synthesis  pathway35,36. Therefore, antibiofilm activity 
observed here is potentially due to bacteriostatic as well as bactericidal effect of UA by disrupting the nucleic 
acid synthesis pathways.
Conclusions
In this work, we loaded graphene flakes with UA and used those to constitute surface coatings with antibiofilm 
properties. We demonstrated that the sustained release of UA from the coatings is the key factor in ensuring a 
strong and long-term antibiofilm effect of our coatings. It is difficult to correlate the findings of such in vitro 
studies—mimicking bacterial attachment to surfaces of biomedical devices—to real life situation in vivo. In our 
in vitro setup, large numbers of bacterial cells are loaded onto the surface. This is a rather advantageous situa-
tion for bacteria, compared to the in vivo conditions. In the human body, human cells compete with bacteria 
for attachment to the surface and the host immune system interferes with bacterial  attachment50,51. While this 
makes a direct comparison between in vitro and in vivo data impossible, it should be said that a 100 000-fold 
reduction of biofilm growth over 96 h, as observed with our coatings in conditions optimal for bacterial attach-
ment (Fig. 6), should be expected to translate to a very effective protection in vivo. We therefore propose that 
UA, loaded onto graphene coatings, could be a very effective means for preventing bacterial colonization of 
biomedical devices and the associated infections.
Figure 6.  Viability of bacteria in 96 h biofilms of (a) S. aureus and (b) S. epidermidis grown on graphene-UA 
coatings. Data represent mean ± standard deviation from 3 independent biological replicates. **P < 0.0001.
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